InvestorsHub Logo
Followers 8
Posts 739
Boards Moderated 0
Alias Born 08/26/2020

Re: None

Wednesday, 02/17/2021 5:01:54 PM

Wednesday, February 17, 2021 5:01:54 PM

Post# of 233061
Something to consider if you believe the FDA has already seen the CD12 top line results:

If those results showed little to no clinical benefit from administration of Leronlimab, do you think the FDA would:

a) Allow the Open Label Extension and eINDs to continue? Or...
b) Shut down administration of Leronlimab for COVID indications?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News